Abstract: Compositions including plant-derived components, optionally administered with CBD, an amount of one or both of magnolol and honokiol effective to provide an antiangiogenic or anti-inflammatory effect that may be useful for reducing cortisol levels and treating a variety of ailments. Furthermore, methods of antiangiogenic or anti-inflammatory and reducing cortisol levels in a human. Plant-derived components of such compositions include magnolol and honokiol as extracts or compounds, or tinctures or solutions and may also include Ashwagandha and/or Magnolia Bark. The compositions may also include other therapeutic compounds such hydroxytyrosol (such as that in olive oil), phospholipids, and carotenoids. The present invention includes methods of treatment of various ailments including anxiety, depression, post-traumatic stress disorder (“PTSD”), stress, insomnia, and drug addiction. The methods may also be used to reduce body weight and/or enhance alertness and focus.

Abstract: Compositions including at least one nuclear steroid family (NSF) receptor antagonist for the treatment or prevention of a coronavirus infection, such as SARS-CoV-2, and for the treatment of symptoms resulting from such infection. Also provided herein are methods of administering such compounds to a patient, either in a combination pharmaceutical formulation or in separate pharmaceutical formulations, to treat or prevent viral infections, including viral infections from coronaviruses such as SARS-CoV-2. Treatment decreases a viral load in a subject and/or may ameliorate symptoms associated with or produced by viral infection. Various administration modalities and mechanisms may be selected depending upon a condition of a patient and the patient's ability to be administered via a selected modality.

Abstract: A method for treating or preventing laminitis is provided comprising administering to an ungulate a therapeutically or prophylactically effective amount of a camelid protease inhibitor. Typically the ungulate is a horse and the camelid protease inhibitor is an inhibitor of equine metalloproteinases and equine serine proteases. The inhibitor may be isolated from blood from healthy camelid or may be generated by inoculating camelid with purified equine metalloproteinase enzymes and serine proteases or with snake venom metalloproteinases, such as those obtained from Bothrops jararaca. The inhibitor may a homodimer antibody or an antigen binding fragment of same. Also provided are compositions comprising such camelid protease inhibitors.

Abstract: A method for the treatment and/or prophylaxis of a viral infection in a subject is provided wherein the method comprises the steps of providing a therapeutically effective amount of a composition comprising an extract of the fruit of Siraitia grosvenori Swingle and administering the composition to the subject. The fruit from which the extract is derived is Luo Han Guo. The extract comprises at least one triterpene glycoside, which may be in the form of a mogroside compound. The extract has been shown to be effective in the treatment of viral infections such as hepatitis C and HIV. Also provided are pharmaceutical compositions comprising at least one triterpene glycoside, or an analogue, metabolite, precursor, derivative, pharmaceutically active salt or pro-drug thereof.

Abstract: A method for the treatment and/or prophylaxis of a viral infection in a subject is provided wherein the method comprises the steps of providing a therapeutically effective amount of a composition comprising an extract of the fruit of Siraitia grosvenori Swingle and administering the composition to the subject. The fruit from which the extract is derived is Luo Han Guo. The extract comprises at least one triterpene glycoside, which may be in the form of a mogroside compound. The extract has been shown to be effective in the treatment of viral infections such as hepatitis C and HIV. Also provided are pharmaceutical compositions comprising at least one triterpene glycoside, or an analogue, metabolite, precursor, derivative, pharmaceutically active salt or pro-drug thereof.

Abstract: Pharmaceutical compositions comprising 5-[2-pyrazinyl]-4-methyl-1,2-3-thione or an analogue, derivative, metabolite, prodrug, solvate or a pharmaceutically acceptable salt thereof; and a pharmaceutical carrier, which promotes association with the outer wall of a subject's digestive tract are described as well as their uses in treating and preventing mucositis and cachexia.

Abstract: A method for treating or preventing laminitis is provided comprising administering to an ungulate a therapeutically or prophylactically effective amount of a camelid protease inhibitor. Typically the ungulate is a horse and the camelid protease inhibitor is an inhibitor of equine metalloproteinases and equine serine proteases. The inhibitor may be isolated from blood from healthy camelid or may be generated by inoculating camelid with purified equine metalloproteinase enzymes and serine proteases or with snake venom metalloproteinases, such as those obtained from Bothrops jararaca. The inhibitor may a homodimer antibody or an antigen binding fragment of same. Also provided are compositions comprising such camelid protease inhibitors.

Abstract: Camelid blood products their peptide isolates and synthetic sequences for wound fluid elevated protease enzyme inhibition. The present invention provides evidence that Metalloprotease and other Protease enzyme (e.g. elastase) peptide inhibitors are present in camelid serum/plasma can be used alone or combined with other agents to enhance healing in the treatment of chronic wounds and burns by inhibiting elevated wound fluid protease activity. These protease enzymes inhibitors present in camelid serum/plasma can be demonstrated to inhibit chronic non-healing wound fluid proteolytic enzymes by the use of wound fluid assay kits specifically designed to measure wound fluid protease activity. The serum/plasma and isolated or synthesised peptides of this patent have use in the treatment of a range of cosmetic skin indications and diseases such as disorders of the gastrointestinal tract, cardiovascular conditions and specifically in the treatment of wound healing and burns and in scar tissue healing.

Abstract: A method for the treatment and/or prophylaxis of a viral infection in a subject is provided wherein the method comprises the steps of providing a therapeutically effective amount of a composition comprising an extract of the fruit of Siraitia grosvenori Swingle and administering the composition to the subject. The fruit from which the extract is derived is Luo Han Guo. The extract comprises at least one thterpene glycoside, which may be in the form of a mogroside compound. The extract has been shown to be effective in the treatment of viral infections such as hepatitis C and HIV. Also provided are pharmaceutical compositions comprising at least one triterpene glycoside, or an analogue, metabolite, precursor, derivative, pharmaceutically active salt or pro-drug thereof.

Abstract: Pharmaceutical compositions comprising 5-[2-pyrazinyl]-4-methyl-1,2-3-thione or an analogue, derivative, metabolite, prodrug, solvate or a pharmaceutically acceptable salt thereof; and a pharmaceutical carrier, which promotes association with the outer wall of a subject's digestive tract are described as well as their uses in treating and preventing mucositis and cachexia.

Abstract: Pharmaceutical compositions comprising 5-[2-pyrazinyl]-4-methyl-1,2-3-thione or an analogue, derivative, metabolite, prodrug, solvate or a pharmaceutically acceptable salt thereof; and a pharmaceutical carrier, which promotes association with the outer wall of a subject's digestive tract are described as well as their uses in treating and preventing mucositis and cachexia.

Abstract: The present invention relates to thalidomide and/or thalidomide analogues and methods for using same to maintain or increase muscle mass to prevent and/or treat sarcopenia. The invention also provides pharmaceutical compositions comprising thalidomide and thalidomide analogues for the prevention and/or treatment of sarcopenia.

Abstract: The present invention provides methods and compositions for the prophylaxis of blood cell disorders such as neutropenia, thrombocytopenia, lymphocytopenia, and anaemia. The invention provides methods wherein compositions comprising at least one cytokinin compound are administered either therapeutically or prophylactically. The invention further has utility in methods of DNA repair.

Abstract: A method for inhibiting growth of bacteria is provided wherein the method comprises the step of administering to a region in need of bacterial growth inhibition an anti-bacterially effective amount of a composition comprising an extract from the plant Eremophila longifolia. The method has utility in the treatment of a number of conditions, including cariogenesis, halitosis, gingivitis and/or periodontitis. The method of the invention may also be used ex vivo to prevent growth of bacterial biofilms on the surfaces of medical devices and other surfaces, such as those found in water systems, ventilation systems, plumbing systems, air conditioners, humidifiers and hot tubs.

Abstract: The present invention provides methods and compositions for the prophylaxis of blood cell disorders such as neutropenia, thrombocytopenia, lymphocytopenia, and anaemia. The invention provides methods wherein compositions comprising at least one cytokinin compound are administered either therapeutically or prophylactically. The invention further has utility in methods of DNA repair.

Abstract: A method for the treatment and/or prophylaxis of a viral infection in a subject is provided wherein the method comprises the steps of providing a therapeutically effective amount of a composition comprising an extract of the fruit of Siraitia grosvenori Swingle and administering the composition to the subject. The fruit from which the extract is derived is Luo Han Guo. The extract comprises at least one thterpene glycoside, which may be in the form of a mogroside compound. The extract has been shown to be effective in the treatment of viral infections such as hepatitis C and HIV. Also provided are pharmaceutical compositions comprising at least one thterpene glycoside, or an analogue, metabolite, precursor, derivative, pharmaceutically active salt or pro-drug thereof.

Abstract: A method for prophylaxis and/or treatment of mucositis comprising the steps of providing a therapeutically effective amount of a composition comprising either (1) at least one compound selected from the group consisting of 5-[2-pyrazinyl]-4-methyl-1,2-3-thione or an analogue, derivative, metabolite, prodrug, solvate or a pharmaceutically acceptable salt thereof; or (2) a cytokinin compound; and administering the composition to a subject in need of such treatment. Also provided are pharmaceutical compositions comprising 5-[2-pyrazinyl]-4-methyl-1,2-3-thione and/or a cytokinin compound and use of these compositions in the preparation of a medicament for the treatment and/or prophylaxis of mucositis. The cytokinin compound may be selected from, but is not limited to N6-isopentenyl adenosine and N6-benzyl adenosine. The compositions may further comprise a chemotherapeutic agent, such as cisplatin.

Abstract: The present invention relates to methods for the treatment of viral influenza using statins, or pharmaceutically effective salts, pro-drugs or metabolites thereof. In particular it is disclosed that statin hydroxyl acid salts including, but not limited to, mevastatin, lovastatin, pravastatin and simvastatin, are effective in conferring resistance to infection with influenza type A viral challenge.

Abstract: The invention provides compositions comprising formula 1 steroids, e.g., 16?-bromo-3?-hydroxy-5?-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16?-bromo-3?-hydroxy-5?-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

Abstract: The present invention provides methods and compositions for the prophylaxis of blood cell disorders such as neutropenia, thrombocytopenia, lymphocytopenia, and anaemia. The invention provides methods wherein compositions comprising at least one cytokinin compound are administered either therapeutically or prophylactically. The invention further has utility in methods of DNA repair.